DekaBank Deutsche Girozentrale Sells 24,050 Shares of Clovis Oncology (CLVS)

DekaBank Deutsche Girozentrale decreased its stake in shares of Clovis Oncology (NASDAQ:CLVS) by 50.3% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,750 shares of the biopharmaceutical company’s stock after selling 24,050 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Clovis Oncology were worth $1,256,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Greenwood Capital Associates LLC grew its position in shares of Clovis Oncology by 21.6% in the fourth quarter. Greenwood Capital Associates LLC now owns 5,605 shares of the biopharmaceutical company’s stock valued at $381,000 after purchasing an additional 996 shares during the period. Element Capital Management LLC purchased a new stake in shares of Clovis Oncology in the fourth quarter valued at $11,400,000. Rice Hall James & Associates LLC grew its position in shares of Clovis Oncology by 21.4% in the fourth quarter. Rice Hall James & Associates LLC now owns 147,650 shares of the biopharmaceutical company’s stock valued at $10,040,000 after purchasing an additional 25,985 shares during the period. Wealthstreet Investment Advisors LLC purchased a new stake in shares of Clovis Oncology in the fourth quarter valued at $3,195,000. Finally, Palo Alto Investors LLC grew its position in shares of Clovis Oncology by 2.2% in the fourth quarter. Palo Alto Investors LLC now owns 3,402,781 shares of the biopharmaceutical company’s stock valued at $231,389,000 after purchasing an additional 73,200 shares during the period.

CLVS has been the subject of a number of recent analyst reports. Credit Suisse Group set a $86.00 price objective on Clovis Oncology and gave the company a “buy” rating in a research report on Thursday, January 18th. They noted that the move was a valuation call. BidaskClub downgraded Clovis Oncology from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Royal Bank of Canada raised Clovis Oncology from a “sector perform” rating to an “outperform” rating and set a $81.00 price objective for the company in a research report on Thursday, February 22nd. Finally, Evercore ISI raised Clovis Oncology from an “in-line” rating to an “outperform” rating and set a $72.00 price objective for the company in a research report on Thursday, February 22nd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and fourteen have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $84.53.

In other Clovis Oncology news, Director Thorlef Spickschen sold 4,500 shares of the business’s stock in a transaction dated Thursday, February 22nd. The stock was sold at an average price of $60.00, for a total transaction of $270,000.00. Following the transaction, the director now owns 16,618 shares in the company, valued at $997,080. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders sold 13,500 shares of company stock worth $816,705 in the last quarter. 12.50% of the stock is owned by insiders.

Shares of Clovis Oncology stock opened at $52.01 on Friday. Clovis Oncology has a twelve month low of $50.79 and a twelve month high of $51.84. The company has a quick ratio of 5.74, a current ratio of 6.55 and a debt-to-equity ratio of 0.92.

Clovis Oncology (NASDAQ:CLVS) last issued its earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.36) by ($0.18). Clovis Oncology had a negative net margin of 545.80% and a negative return on equity of 79.02%. The firm had revenue of $18.50 million during the quarter, compared to analyst estimates of $18.34 million. During the same quarter in the previous year, the business posted ($1.33) EPS. Clovis Oncology’s revenue was up 164.3% compared to the same quarter last year. analysts anticipate that Clovis Oncology will post -5.16 earnings per share for the current year.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Institutional Ownership by Quarter for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply